Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 vs Rituximab in Rheumatoid Arthritis
NCT06475495Phase 2Active, not recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in rheumatoid arthritis (RA), sponsored by Charité – Universitätsmedizin Berlin. Started Dec 2024; status: active, not recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06475495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475495.